A Review of Recurrent Meningiomas with Prolonged Response to Cabozantinib, an Oral Multitarget Tyrosine Kinase Inhibitor

Meningiomas are cerebral cancers that arise from abnormal cell development in the meninges anddefensive layers covering the mind and spinal line. They can attack areas close to the cerebrumtissue and apply tension to neighboring designs, prompting different neurological side effects.Recent advances in atomic science and genomics have revealed insights into the fundamental subatomic adjustments and flagging pathways involved in the improvement of meningoma.Cabozantinib, a chemotherapeutic agent, has shown promising results in preclinical and clinicalstudies in various malignancies, including meningia. It inhibits angiogenesis, reduces cancerdevelopment, and prompts cell passage, providing areas of strength for clinical examination.Inhibition of VEGFR2 signaling has shown promise results in clinical trials in various cancer types,including a variety of cancers. This review summarizes the current knowledge on thepathophysiology and potential therapeutic effects of cabozanteb as a therapeutic agent forintracranial meninga.